These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23052274)

  • 1. [Prostate carcinoma with squamous differentiation after combination endocrine therapy: a case report].
    Nagashima T; Niiro M; Hirayama K; Date S; Okihara K; Mukaisho K
    Hinyokika Kiyo; 2012 Aug; 58(8):457-60. PubMed ID: 23052274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
    Slovin SF
    Nat Clin Pract Oncol; 2007 Sep; 4(9):551-4. PubMed ID: 17728713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safe usage of bicalutamide and goserelin in a male patient with acute intermittent porphyria and prostate cancer.
    Sofie Lichtwarck Bjugn F; Storjord E; Kristensen RM; Brekke OL
    Scand J Urol; 2019; 53(2-3):171-173. PubMed ID: 30714461
    [No Abstract]   [Full Text] [Related]  

  • 4. Volumetric-modulated arc therapy for a pelvic lymph node metastasis from prostate cancer: a case report.
    von Eyben FE; Kangasmäki A; Kiljunen T; Joensuu T
    Tumori; 2013; 99(3):e120-3. PubMed ID: 24158080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
    Montironi R; Diamanti L; Santinelli A; Galetti-Prayer T; Zattoni F; Selvaggi FP; Pagano F; Bono AV
    Pathol Res Pract; 1999; 195(4):201-8. PubMed ID: 10337657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Successful combined treatment with maximal androgen blockade (MAB), intra arterial chemotherapy and radiation for advanced prostatic ductal adenocarcinoma : report of two cases].
    Nishihara C; Kuratsukuri K; Tanaka T; Kawashima H; Nakatani T
    Hinyokika Kiyo; 2011 Apr; 57(4):209-12. PubMed ID: 21646853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case of locally advanced prostate cancer with low serum testosterone associated with intake of an androgenic medicine].
    Sakura M; Tsukamoto T; Yonese J; Nakaishi M; Maezawa T; Takimoto K; Fukui I
    Nihon Hinyokika Gakkai Zasshi; 2003 May; 94(4):529-32. PubMed ID: 12795169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [PRIMARY SQUAMOUS CELL CARCINOMA OF THE PROSTATE: A CASE REPORT].
    Fukui K; Nagasawa S; Hanasaki T; Ueda Y; Aihara K; Kokura K; Matsuo S; Zozumi M; Tsukamoto Y
    Nihon Hinyokika Gakkai Zasshi; 2019; 110(2):129-133. PubMed ID: 32307381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical castration and anti-androgens induce differential gene expression in prostate cancer.
    Lehmusvaara S; Erkkilä T; Urbanucci A; Waltering K; Seppälä J; Larjo A; Tuominen VJ; Isola J; Kujala P; Lähdesmäki H; Kaipia A; Tammela TLj; Visakorpi T
    J Pathol; 2012 Jul; 227(3):336-45. PubMed ID: 22431170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Brainstem metastasis from a prostate adenocarcinoma in the context of Muir-Torre syndrome].
    Aldave G; Pay E; Queipo F; Idoate MA; Guridi J
    Neurocirugia (Astur); 2013; 24(2):78-81. PubMed ID: 23177734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
    Masue N; Hasegawa Y
    Hinyokika Kiyo; 2007 Feb; 53(2):133-5. PubMed ID: 17352166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.
    Sayyid RK; Evans A; Hersey K; Maloni R; Hurtado-Coll A; Kulkarni G; Finelli A; Zlotta AR; Hamilton R; Gleave M; Fleshner NE
    Clin Cancer Res; 2017 Apr; 23(8):1974-1980. PubMed ID: 27756786
    [No Abstract]   [Full Text] [Related]  

  • 14. Degarelix Versus Goserelin Plus Bicalutamide in the Short-Term Relief of Lower Urinary Tract Symptoms in Prostate Cancer Patients: Results of a Pooled Analysis.
    Mason M; Richaud P; Bosnyak Z; Malmberg A; Neijber A
    Low Urin Tract Symptoms; 2017 May; 9(2):82-88. PubMed ID: 28394498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous Metastases From Adenocarcinoma of the Prostate.
    Flores-Terry MÁ; Cruz-Conde de Boom R; García-Arpa M; de Lara-Simón IM
    Actas Dermosifiliogr (Engl Ed); 2018 May; 109(4):360. PubMed ID: 28823393
    [No Abstract]   [Full Text] [Related]  

  • 16. Metastatic prostatic adenocarcinoma mimicking inflammatory breast carcinoma: a case report.
    Njiaju UO; Truica CI
    Clin Breast Cancer; 2010 Feb; 10(1):E3-5. PubMed ID: 20133250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Reevaluation of MAB therapy and progress of endocrine therapy].
    Klotz L; Payne H; Gillatt D; Keane T; Morris C; Akaza H; Hirao ; Akakura K; Fukagai T
    Gan To Kagaku Ryoho; 2005 May; 32(5):705-28. PubMed ID: 15934164
    [No Abstract]   [Full Text] [Related]  

  • 18. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N; Arima K; Sugimura Y
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
    Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
    BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Intermittent androgen deprivation treatment of prostate cancer restarted at low level of serum prostate specific antigen: a pilot study].
    Maekawa S; Maegawa M; Ushida H; Inoue K; Kaneko Y; Ohmori K; Nishimura K
    Hinyokika Kiyo; 2001 Aug; 47(8):553-5. PubMed ID: 11579594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.